 |
|
|
| |
Efficacy and Safety of Switching From
RPV/FTC/TDF or EFV/FTC/TDF to RPV/FTC/TAF in
Black Adults
|
| |
| |
Reported by Jules Levin
9th IAS Conference on HIV Science (IAS 2017)
23–26 July 2017 | Paris, France
Jean-Michel Molina,1 Edwin DeJesus,2 Bart Rijnders,3 Frank A. Post,4
Bernard Vandercam,5 Marcel Stoeckle,6 Anders Thalme,7 Chloe Orkin,8
Ya-Pei Liu,9 Devi SenGupta,9 Huyen Cao9
1Hôpital Saint-Louis, Paris, France; 2Orlando Immunology Center, Orlando, Florida, USA; 3Erasmus MC, Rotterdam, the Netherlands; 4King's College Hospital, London, UK; 5Cliniques universitaires Saint-Luc, Bruxelles, Belgique; 6Medizinische Poliklinik,
Universitätsspital Basel, Switzerland; 7Karolinska Universitetssjukhuset, Stockholm, Sweden; 8The Royal London Hospital, Barts Health NHS Trust, London; 9Gilead Sciences, Inc., Foster City, California, USA
|
| |
|
|
|
|
|
